2020 speakers include - oxford global · including fusion proteins, antibody-drug conjugates,...

If you’re on Twitter, make sure to follow us Biologics Series @biologicsconf

13th Annual Proteins & Antibodies Congress

Day 2 Stream 1 - Antibody Engineering, Screening, Design

• Innovative design and engineering approaches

• Advanced antibody structures and dynamics

• Genome editing in antibody engineering

• Antibodies against challenging targets

• Novel antibody formats

• Machine learning in antibody discovery and antibody

engineering using deep learning

• Library design

• Display technologies:

o Phage

o Yeast

Day 2 Stream 2 - ADC Engineering, Bioconjugates and Fusion

Proteins

• Immunogenicity of therapeutic antibodies: prediction and risk

mitigation

• Validating novel ADC targets

• Bioconjugation strategies to improve half-lives, specificity and

distribution

• Other novel bioconjugation strategies

• Fusion proteins

2nd Annual Bispecifics in Discovery & Development Congress

Day 2 Stream 3 - Bispecifics Discovery, Therapeutic

Development and Developability Considerations

• Targeting Solid or Liquid Tumors - Novel Discovery and

Platforms

• T-Cell Re-direction and T-Cell-engaging Molecules

• Antibody design in Bi-specifics – antibody engineering

• Validating Novel Applications

• Enhancing Product Developability

• Tri-Specific and Multispecific – future opportunities and

therapeutic potential

Day 3 Stream 4 - Applications of Bispecifics &

Multispecifics

• Immunogenicity, aggregation, safety and toxicity

considerations

• Implementing developability processes and maximizing

clinical performance

• Biomarker analysis and translation

• Clinical development of bispecific and multispecific

• Case studies of bispecific clinical development in different

therapeutic areas:

o Immuno-oncology, metabolic diseases and

infectious diseases, Autoimmune disease

• Taking bispecific to the clinic and solid tumors

Day 3 Stream 1 –

Part 1 - Part 1 – Antibody Engineering, Development & Generation

• Advances in antibody engineering

• Latest development strategies

Part 2 – Biotherapeutics Discovery & Development: Non-Oncology

Indications

• Going beyond oncology:

o Autoimmune diseases

o Infectious diseases

o Inflammation

o Neuroscience

o Cardiometabolic diseases

Day 3 Stream 2 - Bioanalysis: Latest Techniques & Manufacturing

Updates and PKPD

• Bioanalytical strategy for Car-T and cell therapies

• Novel technologies & techniques to analyze biotherapeutics

• Clinical development for Car-T

• Advanced manufacturing technologies:

o MAM

o PAT

• Continuous manufacturing & automation

• Digitalization

• PKPD

Day 3 Stream 3 - Protein, Antibody Production Development –

Purification & Expression

• Advances in engineering stable and transient cell lines

• CHO cell line development to improve protein expression

• Cell line development for biotherapeutics

• Recombinant protein production

• Difficult-to-express proteins

2020 Speakers Include:

John McCafferty Sophia Karagiannis William Olson

IONTAS King’s College London Regeneron

Meet Senior Decision Makers

500 senior attendees from leading pharmaceutical,

biopharmaceutical, academics, CRO and solution provider

companies will be attending. Meet Senior VPs, Directors, &

Managers with the following job titles:

Protein Structure

Bioanalysis

Biologics Manufacturing

Antibody Technology

Antibody Discovery

Antibody Therapies

Discover New Solutions

Formal and informal meeting opportunities offer delegates the

chance to discuss key solutions with leading service providers.

Services to be discussed include:

Expression Platforms

Conjugation Technologies

Display Technologies

Modelling Platforms

Tissue Processing

Developability Assessment

https://twitter.com/biologicsconf

2020 Proteins & Antibodies Congress Confirmed Speakers:

• Tristan Vaughan, Vice President R&D, Antibody Discovery & Protein Engineering, AstraZeneca

• Stanislas Blein, Vice President, Head of Antibody Engineering, Glenmark Pharmaceuticals

• John McCafferty, Chief Executive Officer, IONTAS Pharmaceuticals

• Mahendra Deonarain, Chief Executive and Science Officer, Antikor Biopharma

• Andrew Porter, Chief Technology Officer and Professor of Medical Biotechnology, Elasmogen and University

of Aberdeen

• Surinder Kaur, Director and Senior Scientist in BioAnalytical Sciences/ADT, Genentech

• Kristin Brown, Director, Molecular Design US, GlaxoSmithKline

• Xiaona Jing, Director, Global CMC And Pharmaceutical Development, NBE Therapeutics

• Laurence Fayadat-Dilman, Senior Director, Protein Sciences Head, Discovery Biologics, MSD

• Richard Smith, Director, Preclinical, Amgen

• Inga Norby, Expression Technologies 2, Director, Novo Nordisk

• Laura von Schantz, Director, Antibody Engineering, Alligator Bioscience

• Anup Zutshi, Director, Head of Translational Quantitative Pharmacology-USA, EMD Serono

• Stephen Ashman, Director, Head of High-Throughput expression and Characterization, GlaxoSmithKline

• Francisca Wollerton, Director of Antibody Engineering, F-star Biotechnology

• Colette Johnston, Senior Director, Early Discovery, Crescendo Biologics

• Henrik Sune Ramírez-Andersen, Scientific Director, Novo Nordisk A/S

• Frank Thielmann, Operational Excellence Director - Region Europe, Takeda

• Andrew Sanderson, Scientific Leader, GlaxoSmithKline

• Maria Groves, Associate Director, Head of the CRUK AstraZeneca Antibody Alliance Laboratory, AstraZeneca

• Stefan Zielonka, Associate Director, Protein Engineering & Antibody Technologies, Merck KGaA

• Trevor Wilkinson, Associate Director, AstraZeneca

• Seema Kumar, Associate Director, MSD

• Rob de Jong, Associate Director, Antibody Research & Technology, Genmab

• Jacques Dumas, Head of Protein Sciences & Technology, Sanofi

• Patrick Garidel, Head of Process, Purification and Pharma Development, Boehringer Ingelheim

• Alistair Henry, Head, Discovery Science, UCB

• Denise Steckel, Head, Clinical Collaborations Management, Genentech

• Yang Yang, Scientific Technical Leader, Novartis

• Ciarán Cronin, Associate Research Fellow, Head Parallel Protein Production Group, & Group Leader Gene-to-

Structure, Pfizer

• Claudio Sustmann, Head Program Management & External Innovation; Large Molecule Research, Roche

Pharmaceuticals

• Robin Löving, Chief Scientific Officer, Salipro Biotech

• Hiroki Shirai, Executive Fellow, Modalities Research Laboratories, Astellas

• Paul Wassmann, Analytical Strategy & Science Lead, Novartis

• Wendy Sandoval, Principal Scientific Manager in Research, Genentech

• Noel Byrne, Expression Group Lead and Associate Principal Scientist, Merck Research Laboratories

• Lorenzo Benatuil, Senior Principal Research Scientist, AbbVie

• James Apgar, Senior Principal Scientist, Pfizer

• Lauren Ely, Senior Principal Scientist, Pfizer

• Darren Bates, Principal Scientist, Amgen

• Sabine Imhof-Jung, Principal Scientist, Roche Pharma

• Stephan Dickgiesser, Principal Scientist, Merck KGaA

• Fionnuala McAleese Eser, Antibody Lead Discovery 1, Bayer AG

• Smita Raghava, Associate Principal Scientist, Sterile Formulation Sciences, MSD

• Marc Pompiati, Senior Scientist, Roche Pharmaceuticals

• Xin Yu, Senior Scientist, Amgen

• Rajbharan Yadav, Scientist, Development Sciences, Genentech

• Chawaree Chaipan, Investigator II, Novartis

• Jennifer Drew, Investigator, GlaxoSmithKline

• Magdalena Sips, Senior Scientist, Argenx

• Itai Benhar, Professor, Tel Aviv University

• Nicholas Brindle, Professor of Cell Signalling, University of Leicester

• Colin Self, Emeritus Professor, Newcastle University

2020 Proteins & Antibodies Congress Confirmed Speakers Continued:

• Sophia Hober, Professor of Molecular Biotechnology, KTH Royal Institute of Technology

• Sophia Karagiannis, Professor of Translational Cancer Immunology and Immunotherapy, King’s College

London

• Mark Cragg, Professor of Experimental Cancer Research, University of Southampton

• E. Sally Ward, Professor, University of Southampton

• Alexander Frey, Associate Professor, Molecular Biotechnology, Aalto University

• Vito Fodera, Principal Investigator and Associate Professor of Biophysics, University of Copenhagen

• Jerry Heng, Reader in Particle Technology, Imperial College London

2020 Panel Discussion and Roundtable Moderators:

• Ho Cho, Vice President, Biotherapeutics, Celgene

• Shawal Spencer, Investigator, Biopharm CLD Disruptive Technologies, GlaxoSmithKline

• Kati Räsänen, Senior Scientist, Biologics, Orion Pharma

• Galahad Deperalta, Senior Scientist, Genentech

2020 Bispecifics in Drug Discovery & Development Congress Confirmed Speakers:

• Chengbin Wu, Founder and Chief Executive Officer, EpimAB Biotherapeutics

• Nathan Trinklein, Chief Technology Officer, TeneoBio

• Mark Throsby, Chief Scientific Officer and Executive Vice President, Merus

• Nicolas Fischer, Chief Executive Officer, Light Chain Bioscience – A brand of Novimmune SA

• William Olson, Vice President, Therapeutic Proteins, Regeneron

• John Delaney, Director, Research Technologies and Collaborations, Amgen

• Boris Gorovits, Senior Director and Head of the Non-Clinical and Clinical Bioanalysis Group BioMedicine

Design, Pfizer

• Robert Pejchal, Director, Antibody Engineering, Adimab

• Jennifer Fretland, Head of DMPK US, Sanofi

• Rachel Mulvaney, Senior Scientist, Immunocore

• Adam Root, Senior Principal Scientist, Pfizer

• Guy Georges, Senior Principal Scientist, Roche Pharmaceuticals

• John Blackwood, Senior Research Scientist, Kymab

• Marlon Hinner, Principal Scientist and Group Leader, Roche Pharmaceuticals

• Christina Claus, Senior Scientist, Roche Pharmaceutical Research and Early Development (pRED)

• Youssef Hijazi, DMPK Expert, Sanofi

• Bellos Hadjivassiliou, Scientist II, Celgene

Benefits to Attending

✓ Hear from and meet with the key innovators in proteins, antibodies and bispecifics. 2019 speakers Included: Chief

Medical Officer, MSD; Senior Vice President, IPSEN; Scientific Director, Novo Nordisk A/S

✓ Discover collaborative solutions protein & antibody engineering. Topic areas to be covered include novel antibody

formats, novel approaches to protein engineering as well as computational & analytical tools

✓ Discuss the latest innovations in protein and antibody-based biotherapeutics. Discuss targeting immune checkpoints,

advancing T cell engager therapies and hear case studies from beyond oncology

✓ New to 2020! Learn more about bioanalysis, PKPD & manufacturing. Areas to be covered include stability testing,

characterisation updates, continuous manufacturing and clinical development for Car T

✓ New to 2020! Featuring highly interactive kick-off sessions focusing on protein engineering, bioanalysis and oncology &

immune-oncology biotherapeutics

2020 Biologics Series UK Sponsors:

Platinum Sponsors:

Gold Sponsors:

Silver Sponsors:

Bronze Sponsors:

Networking and Programme Sponsors:


Kick-Off Sessions – 27th April 2020

08.00 – 08.30 Registration

08.30 – 11.30 Workshop led by:

Chemical Computing Group

11.00 – 11.30 Registration & Welcome Refreshments

Kick-Off Session 1: Protein Engineering, Expression, Design &

Selection

• Novel approaches to protein engineering

• Developing novel expression systems

• Engineering and optimising fusion proteins

• Improving protein half-life extension, potency & selectivity

• Machine learning guided protein engineering

• Computational and analytical tools for protein engineering:

o Evaluating new modeling softwares & platforms

Kick-Off Session 2: Bioanalysis: Characterisation,

Stability Testing And Formulation Development

• Characterization methods and platforms for biologics

• Bioanalysis for ADCs

• Stability testing

• Optimization and developability assessment

• Formulation development

• Impurity testing

• Understanding protein aggregation

• CMC considerations for bispecifics

Kick-Off Session 3: Biotherapeutics: Discovery &

Development – Oncology & Immuno-Oncology

• Targeting immune checkpoints and developing

next generation immune checkpoints

• Advancing T-Cell engager therapies

• Applying structural biology to the discovery and

development of therapeutic antibodies

• Combination therapies and lessons learned

• Supporting biotherapeutics collaborations

Supported By:

Supported By:

Supported By: TBC




Selection





11.30 – 12.00 Kick Off Session Keynote:

Novel Approaches To Protein Engineering

Kristin Brown, Director, Molecular Design US, GlaxoSmithKline

Kick Off Session Keynote:

Hybrid Immunoaffinity LC-MS/MS Bioanalysis In

Biologics Drug Development

Small molecule bioanalysis is typically performed by LC-MS/MS,

whereas, ELISA is the commonly used method for the

quantification of protein biotherapeutics. More recently protein

biotherapeutics are often structurally complex, with formats

including fusion proteins, antibody-drug conjugates, bispecifics,

antibody fragments and cyclic peptides. This has lead to the

development of new hybrid bioanalytical strategies involving

affinity capture (IA) and LC-MS/MS as an alternative approach

for protein bioanalysis. Key advantages of hybrid methods

include high selectivity, minimal matrix effects, and multiplexing

capabilities. Signature peptides unique to the therapeutic mAb

can be identified by performing in silico digestion with trypsin

and are used for quantification of the protein. Various analyte

enrichment approaches can be evaluated to develop an IA LC-

MS/MS method for the quantification of a biotherapeutic.

Reagents that are not of suitable quality for ELISA may be used

in the affinity capture analyte enrichment step of hybrid IA LC-

MS/MS. For antibodies, generic binding enrichment reagents

such as protein A may be used to determine “total”

biotherapeutic concentrations. Specific reagents such as target

antigen or anti-idiotypic antibodies may be used to determine

“free” therapeutic concentrations. This talk will present

highlights of IA LC-MS/MS pharmacokinetic assay development

and validation with a variety of nonclinical and clinical

drug development case studies.

Surinder Kaur, Director and Senior Scientist in

BioAnalytical Sciences/ADT, Genentech

Kick Off Session Keynote: Evaluation Of Immune Response To Bi-Specific

Antibodies And Other Complex Biotherapeutics

Presentation will focus on the current understanding of

the assessment of host immunogenicity response to

multi-domain biotherapeutics, including bi-specific

antibodies, protein fusion molecules and other complex

therapeutics. Related immunogenicity risk factors,

required immunogenicity response characterization and

related methodologies will be discussed. Current

position of regulatory agencies will be reviewed.

Boris Gorovits, Senior Director and Head of the

Non-Clinical and Clinical Bioanalysis Group

BioMedicine Design, Pfizer

12.00 – 12.30 Roundtable Discussions:

Table 1: Advances In Protein Engineering

Moderator: Ho Cho, Vice President, Biotherapeutics, Celgene

Roundtable Discussions Roundtable Discussions:

Table 2: ADC Combinatorial Strategies

• Non-IO combinations for ADCs

• ADC and immuno-oncology combinations

Moderator: Kati Räsänen, Senior Scientist,

Biologics, Orion Pharma



12.30 – 13.15 Lunch


Selection





13.15 – 13.45 Development Of Predictive Tools To Improve Antibody

Properties

James Apgar, Senior Principal Scientist, Pfizer

Native Chromatographies To Resolve Mispairs And

Determine Optimal Chain Pairing For Bispecific

Antibodies

• Analytical methods involving MS coupled native

chromatographies will be discussed which aim to both

resolve and characterize impurities resulting from the

single cell assembly of bispecific antibodies

• Distinguishing the ‘correct’ BsIg from the isobaric light

chain‐scrambled mispair is a particular challenge due to

the similarity of the molecules

• We investigate chromatographic elution order through

analytical methods and molecular modeling in an effort to

understand the intrinsic charge, size and shape

differences

Wendy Sandoval, Principal Scientific Manager in

Research, Genentech

Identifying New Immuno-Oncology Targets

Xin Yu, Senior Scientist, Amgen

13.45 – 14.15 Sponsor Presentation

Sponsor Presentation Sponsor Presentation

14.15 – 14.45 Panel Discussion: Advances & Latest Technology Developments

In Protein Expression

Panel Moderator:

Shawal Spencer, Investigator, Biopharm CLD Disruptive

Technologies, GlaxoSmithKline

Panel Discussion

Panel Moderator:

Galahad Deperalta, Senior Scientist, Genentech

Panel Discussion

14.45 – 15.15 Targeting Bi-Specific Biologics To Disease Tissues

Exploring Formulation Design Space For Complex BiologicsBi-specific

biologics such as dual variable domain immunoglobulins (DVD-Igs)

offer new opportunities for innovative tissue/disease targeted

therapies and have permitted the exploration of tissue specific and

disease tissue specific targeting of biologics. We will describe preclinical

examples of tissue targeting in normal and disease in vivo models as

part of a new generation of locally acting “regio-specific” biologics

therapies.

Lorenzo Benatuil, Senior Principal Research Scientist, AbbVie

Deciphering The Heterogeneity Of Visible And

Subvisible Protein Aggregates

• Advanced methods for the detection of protein aggregates

• Ensemble heterogeneity of protein aggregates

• Morphological and structural analysis of different

aggregates

Vito Fodera, Principal Investigator and Associate

Professor of Biophysics, University of Copenhagen

Developing A Novel Biologics Platform Based On

Shark VNAR Single-Domains With A Focus In

Oncology

Andrew Porter, Chief Technology Officer and

Professor of Medical Biotechnology, Elasmogen

and University of Aberdeen




Selection





15.15 – 15.45 Combinatorial Protein Engineering

Darren Bates, Principal Scientist, Amgen

Predicting Antibody Developability Profiles Through

Early Stage High-Throughput Screening

Smita Raghava, Associate Principal Scientist, Sterile

Formulation Sciences, MSD

Working With Clinical Collaborators In

Combination Studies

• Why we do combination trials

• Working with Collaborators to optimize

performance

• Key factors for success in Collaborator work

• Advantages, Challengers & Lessons learned to date

on the is journey

Denise Steckel, Head, Clinical Collaborations

Management, Genentech

15.45 – 16.00 Refreshments

16.00 – 16.10 Oxford Global’s Welcome Address

16.10 – 17.10 Welcome Keynote: Biologics Discovery At AstraZeneca

Three case studies will be presented describing different aspects of drug discovery. The first will describe the affinity maturation of an antibody that blocks enzyme function and compares the co-

crystal of the lead mAb with that of the affinity matured variant. The second will describe the challenges relating to intracellular delivery of biologics and how they can be overcome, and the final case

study will illustrate the use of machine learning in antibody discovery.

Tristan Vaughan, Vice President R&D, Antibody Discovery & Protein Engineering, AstraZeneca

17.10 – 18.10 Drinks Reception

13th Annual Proteins & Antibodies Congress and 2nd Annual Bispecifics in Discovery & Development Congress

Day Two – 28th April 2020

13th Annual Proteins & Antibodies Congress and 2nd Annual Bispesifics in Discovery & Development Congress

07.30 – 08.20 Registration

08.20 – 08.30 Chairperson’s Welcome Address

13th Annual Proteins & Antibodies Congress 2nd Annual Bispesifics in Discovery & Development Congress

Antibody Engineering, Screening, Design, Development ADC Engineering, Bioconjugates And Fusion Proteins Bispecifics Discovery, Therapeutic Development And

Developability Considerations

08.30 – 09.00 Stream Keynote Address:

Construction And Screening Of Phage Display Libraries

Richard Smith, Director, Preclinical, Amgen

Stream Keynote Address:

Analytical Strategy Considerations And Examples To

Assess Complex Therapeutic Proteins

• Developability assessment concept at Novartis

• Tool-box concept for Therapeutic proteins in

comparison to standardized approach for mAbs

• Analytical strategy setting and analytical method

optimizations on example of an Fc-fusion protein

Paul Wassmann, Analytical Strategy & Science Lead,

Novartis


Bi- And Mono-Specific ADCs Delivering Cytotoxic And Anti-

Inflammatory Drugs

• Bispecific and biparatopic antibodies can optimally modulate

receptor pharmacology, internalization and payload delivery

• Linking glucocorticoid steroids to macrophage-targeting

antibodies offers a targeted approach to treating inflammation

William Olson, Vice President, Therapeutic Proteins,

Regeneron

09.00 – 09.30 The Generation Of Formatted Multispecific

Therapeutics For Immuno-Oncology – Platform

Updates

• Crescendo Biologics has a proprietary transgenic mouse

platform for generation of fully human VH domains

(Humabody VH)

• Crescendo uses this platform for the generation of

formatted multispecific therapeutics for immuno-

oncology

• The talk will describe the various discovery cascades

Crescendo uses to identify the most potent formatted

molecules with the best developability characteristics

• Different approaches will be described and compared

including isolation of VH using in-format display and NGS

approaches

• Case studies will be described

Colette Johnston, Senior Director, Discovery,

Crescendo Biologics

Technology Development For ADC Engineering

Alistair Henry, Head, Discovery Science, UCB

The Future Of Biologic Therapeutics And Their Unique

Challenges

John Delaney, Director, Research Technologies and

Collaborations, Amgen




Antibody Engineering, Screening, Design,

Development

ADC Engineering, Bioconjugates And Fusion Proteins Bispecifics Discovery, Therapeutic Development And


09.30 – 10.00 Solution Provider Presentation

Solution Provider Presentation

For sponsorship opportunities please contact

[email protected]


For sponsorship opportunities please contact

[email protected]

10.00 – 11.20 Morning Coffee & Refreshments, One to One Meetings, Poster Presentation Sessions

11.20 – 11.50 Modulating The Receptor Binding Site Of

Immunoligands For Enhanced Potency And Efficacy

• Methods for library construction (Yeast display) of

immune-ligands

• Selection strategies

• Optimization of immune cell activation

Stefan Zielonka, Associate Director, Protein

Engineering & Antibody Technologies, Merck KGaA

Understanding TNFR Agonism 1) TNFR are agonised through clustering

2) TNFR agonism is epitope and Fc dependent

3) Rules may differ for differing members of the TNFR family

Mark Cragg, Professor of Experimental Cancer

Research, University of Southampton

Clinical Stage Bispecific Antibodies

Stanislas Blein, Vice President, Head of Antibody Engineering,

Glenmark Pharmaceuticals

11.50 – 12.20 Synthetic DNA Technologies Enable Single Domain

Antibody Discovery

• Utilizing its proprietary DNA writing technology to create

oligo pools, genes, and synthetic libraries, Twist Pharma,

a division of Twist Bioscience, provides the

biotechnology industry with an end-to-end antibody

discovery solution

• One solution is our panel of high-quality human single

domain libraries (sdAb)

• We will show proof-of-concept screens with these

libraries and examples of how modular these sdAb’s are

for bispecific antibody development

Aaron Sato, Chief Scientific Officer, Twist Bioscience


For sponsorship opportunities please

contact

[email protected]

Novel Transposase Tools For Cell-Line Development

• ATUM has discovered, characterized and engineered new

transposases

• The technology is highly valuable for protein expression and

genome engineering applications

• The Leap-In transposases enable efficient integration and are able

to integrate large payloads

• The technology significantly accelerates stable pool and cell line

generation

Claes Gustafsson, Chief Commercial Officer and Co-Founder,

ATUM

mailto:[email protected]







Development






contact

[email protected]



contact

[email protected]

12.50 – 13.50 Lunch, Poster Presentation Sessions

13.50 – 14.20 Format-Function Relationship And Application In

Therapeutic Antibody Development At Roche

Claudio Sustmann, Head Program Management &

External Innovation; Large Molecule Research, Roche

Pharmaceuticals

Translating Antibody Fragment Drug-Conjugates

(FDCs) From Concept To Clinic

Antibody Drug Conjugates (ADCs) are failing due to 3 critical

limitations: Low potency, ineffective solid-tumour penetration

and poor tolerability. The industry is full of approaches where

full-length IgGs have been engineered to carry defined

numbers of payloads and higher-loadings of less potent

payloads appear to be well-tolerated. However, Antibody

fragments (e.g. scFvs), which have many advantages including

rapid tumour penetration, faster clearance, Inexpensive

manufacture have been technologically challenging to apply

in oncology. Our approach enables scFvs to have a high DAR

leading to a new product class tailored for solid tumours.

Antikor has two lead products for solid tumours: anti-HER2

FDC (ANT-043) and an undisclosed target (ANT-045). ANT-043

has excellent tumour killing and superior tolerability in rat

toxicology studies. In partnership with a premier Hong Kong-

based biopharma, Essex Biotechnology, Antikor is taking ANT-

043 into IND-enabling studies and will present preclinical

data. In a new development, ANT-045, which emerged from

Antikor’s novel and proprietary FDC discovery engine, is

progressing well and new data will illustrate how ANT-045

could have a broader patient benefit in gastro-intestinal

cancers. This presentation will focus on Antikor’s FDC

discovery platform (stable high-DAR scFv-display libraries,

tailored linker-payloads and design features) that has the

potential to generate a valuable pipeline of new products

promising to succeed where ADCs have failed to deliver.

Mahendra Deonarain, Chief Executive and Science

Officer, Antikor Biopharma

A Novel Bispecific Antibody Platform That Elicits Efficient

Tumor Lysis With Minimal Cytokine Release In Liquid And Solid

Tumors

Nathan Trinklein, Chief Technology Officer, TeneoBio





13th Annual Proteins & Antibodies Congress 2nd Annual Bispecifics in Discovery & Development Congress


Development



14.20 – 14.50 IgE Class Antibodies For Cancer Immunotherapy

• We designed antibodies recognising tumour-associated

antigens with Fc regions of the IgE class, aiming to

harness effector functions of IgE class known to mediate

immune immune clearance of parasites

• Anti-tumour IgE potentiated restriction of tumour

growth in several in vivo models of cancer and

potentiated recruitment and activation of macrophages

in the tumour microenvironment

• Our first-in-class IgE antibody has reached clinical study,

offering the chance to activate previously untapped

immune mechanisms against solid tumours

Sophia Karagiannis, Professor of

Translational Cancer Immunology and

Immunotherapy, King’s College London

Developing Antibody Drug Conjugates (ADC) To

Deliver A Warhead Or Toxin To Cancer Cells

Maria Groves, Associate Director, Head of the CRUK

AstraZeneca Antibody Alliance Laboratory,

AstraZeneca

Bispecific Discovery & Development Platform Updates

Mark Throsby, Chief Scientific Officer and Executive Vice

President, Merus

14.50 – 15.20 Antibody-Mediated Inhibition Of Sema3A Promotes

Cell Migration, Axonal Growth And Retinal Ganglion

Cell (RGC) Survival Upon Insults To The Eye

• Semaphorin 3A (Sema3A) is an axonal guidance

molecule. Previously we provided a proof of concept for

the therapeutic approach for neuroprotection via

inhibiting the Sema3A pathway

• To further develop potent and specific anti-Sema3A

inhibitors we isolated anti-Sema3A antibodies from a

human antibody library

• The Sema3A inhibitory antibodies abolished the Sema3A

effects on scratch and repulsion assays in vitro and were

protective in several eye injury models in rats and

rabbits

Itai Benhar, Professor, Tel Aviv University

SMAC™ iADC™: From Lab Bench To Clinical Supply

• Overview of challenges faced by conventional ADCs, and

what new opportunity enzymatic conjugation could

bring to ADC development.

• The successful transformation of NBE’s innovative ADC

technology to GMP manufacturing platform.

• How to handle CMC outsourcing management in

Biotech SMEs

Xiaona Jing, Director, Global CMC And Pharmaceutical

Development, NBE Therapeutics

Workshop Part I

15.20 – 16.20 Afternoon Coffee & Refreshments, One to One Meetings, Poster Presentation Sessions




contact

[email protected]

Workshop Part II





2nd Annual Bispecifics in Discovery & Development Congress


Development



16.50 – 17.20 Antibody Discovery, Affinity Maturation And

Developability Screening From Large Mammalian

Display Libraries

• Using CRISPR/Cas9 large libraries of 10 million

monoclonal stable cell lines have been constructed

where each cell contains a single antibody gene/cell

inserted at a single locus

• IgG-formatted antibodies are displayed on the surface

permitting selection from the library of clones encoding

desirable binding properties using flow cytometry

• The system is sensitivity to “developability” issues such

as aggregation propensity and polyreactivity allowing

detection and avoidance of problematic antibodies

during the initial discovery phase

John McCafferty, Chief Executive Officer, IONTAS

Pharmaceuticals

Engineering Antibody-Drug Conjugates For Improved

Drug Delivery

Despite major advances in the generation of antibody-drug

conjugates (ADCs), their efficacy is frequently limited by dose-

limiting toxicities. Further, high levels of target are usually

required for therapeutic effects. To overcome these

limitations, we have engineered the HER2-specific antibody,

pertuzumab, to bind to target with substantially higher

affinity at near neutral pH than at acidic, endosomal pH. The

engineered variants have been used to generate ADCs that

deliver their cytotoxic payload to lysosomes at substantially

higher levels than their parent ADC comprising wild type

pertuzumab. These ADCs, or ALTAs (for ADCs with increased

Lysosomal Trafficking Activity), are also more effective than

their parent ADC or the clinically approved ADC, trastuzumab-

DM1, in reducing the growth of tumor xenografts that

express intermediate levels of HER2. The ALTA technology

not only has applications for the treatment of tumors with a

broad range of HER2 expression levels, but also in the

targeting of other tumor markers and types.

E. Sally Ward, Professor, University of Southampton

Bispecifics: Considerations For Development

Anup Zutshi, Director, Head of Translational Quantitative

Pharmacology-USA, EMD Serono

17.20 – 17.50 In Silico Selection Of Lead Antibodies

The third complementarity determining region of heavy chain

(CDR-H3) in antibodies plays significant role for antigen

recognition. Using our high resolution antibody modeling

technology which proved competitive at antibody modeling

assessment II (AMA-II), we’ve found that the structural

versatility of CDR-H3 is key to predict the difficulty in

engineering step.

Hiroki Shirai, Executive Fellow, Modalities Research

Laboratories, Astellas

Straightforward Generation Of Site-Specific ADCs

Stephan Dickgiesser, Principal Scientist, Merck KGaA

Developing Breakthrough Therapies As Bispecific Antibodies

• Bispecific antibody technology FIT-Ig shows favorable drug-like

properties and manufacturing efficiency

• Tetra-valent binding properties are preferred in dual-targeting

mechanism for cancer treatment

• Bispecifc antibodies can induce degradation of target receptors

on target cells

• Considerations in optimization of T cell engager bispoecific

antibodies

Chengbin Wu, Founder and Chief Executive Officer, EpimAB

Biotherapeutics



13th Annual Proteins & Antibodies Congress – Pre-Dinner Roundtable Discussions 2nd Annual Bispecifics in Discovery & Development Congress

17.50 – 18.30 Table 1 – Challenges In Biotherapeutics Manufacturing

• Automation and digitalization of manufacturing

• Challenges in upstream and downstream as well as fill & finish processes

• New manufacturing technologies

Moderator: Frank Thielmann, Operational Excellence Director - Region Europe, Takeda

Table 2 – Advanced Antibody Engineering Technologies

Table 3 – Bioconjugates

Using Unbiased Peptide Libraries To Understand TCR-Antigen

Specificity

• Immunocore have developed a soluble T cell receptor (TCR)-based

bispecific therapeutics platform (ImmTAC®)

• TCR-antigen specificity is critical to avoid off target toxicity

• Peptide specificity profiles can inform a rationalised TCR

engineering approach that prioritises specificity

Rachel Mulvaney, Senior Scientist, Immunocore

18.30 – 19.00 Updates On Development And Applications Of Roche’s

Bispecific Platform

Marlon Hinner, Principal Scientist and Group Leader, Roche

Pharmaceuticals

19.00 End of Day One & Congress Dinner


Day Three – 29th April 2020

13th Annual Proteins & Antibodies Congress 2nd Annual Bispecifics in Discovery &

Development Congress

Part 1 – Antibody Engineering, Development

& Generation

Bioanalysis: Latest Techniques &

Manufacturing Updates

Protein & Antibody Production

Development: Purification & Expression

Applications Of Bispecifics &

Multispecifics

08.30 – 09.00 Stream Keynote Address:

Improving The Manufacturability Of An Fc

Fusion Protein Through Directed Evolution

And Structure-Based Protein Engineering

• Structure-based design was combined with

directed evolution on yeast to improve the

thermal stability of a biotherapeutic Fc fusion

protein

• The engineered molecule maintains affinity

and selectivity while showing increased in vitro

efficacy and manufacturability

Lauren Ely, Senior Principal Scientist, Pfizer

Stream Keynote AddressL

Efficiency Improvements In

Biotherapeutics Manufacturing

• Application of Lean tools in drug substance

and drug product manufacturing

• Use of digital tools to improve efficiency

• Data mining and modelling for process

improvements

Frank Thielmann, Operational Excellence

Director - Region Europe, Takeda

Predictive Stability & Properties For The

Pharmaceutical Development Of Biologics

• In silico tools: current applications

• The application of “Arrhenius” for biologics

• Advances in predicting protein aggregation

propensity

Patrick Garidel, Head of Process,

Purification and Pharma Development,

Boehringer Ingelheim


Somapacitan, A Long-Acting Human

Growth Hormone By Non-Covalent

Albumin Binding

The presentation will describe the

development of somapacitan a long acting

human growth hormone (hGH) conjugate

based on non-covalent reversible albumin

binder technology with an extended in vivo

half-life and duration of action. The

identified position L101C - achieved using

positional cysteine scan in combination

with a diverse set of albumin binders - was

used to conjugate a structurally diverse set

of albumin binders. The conjugates were

conveniently obtained by alkylation to the

introduced L101C cysteine using halo-

acetamide functionalised albumin-binding

side chains. In vitro and in vivo profiling

provided the basis for identification of the

optimal growth hormone and albumin

binder site chain composition, when both

sufficient receptor binding and a suitably

long half-life was to be attained in order to

yield a molecule with potential for a once-

weekly dosing regimen.

Henrik Sune Ramírez-Andersen,

Scientific Director, Novo Nordisk A/S






& Generation






Multispecifics

09.00 – 09.30 Therapeutic IgG Antibody Combinations

Acting As Bio-Logic AND Gates

• We present the HexElect® platform, a two

component concept based on Fc domain

engineered IgG antibody pairs that act as Bio-

Logic AND gates selectively activated after

hetero-hexamerization

• Pairwise IgG hetero-hexamerization

dependent initiation of effector functions such

as complement activation or target signaling

were strictly mutually dependent on the

presence of two targets co-expressed at the

same cell surface

• The HexElect platform may enable access to

an untapped, combinatorial target space for

the generation of antibody therapeutics that

exhibit both selectivity and potency

Rob de Jong, Associate Director, Antibody

Research & Technology, Genmab

Crystallisation As An Alternative

Downstream Bioseparation Technology

• Control of nucleation and crystallisation

• Selective crystallisation for bioseparation

and biopurification

• Scale up and continuous crystallisation in

DSB

Jerry Heng, Reader in Particle Technology,

Imperial College London

Enabling The Development Of Ultimate

Recombinant Production Possibilities For

New Therapeutic Proteins

Inga Norby, Expression Technologies 2,

Director, Novo Nordisk

Discovery and Optimization Of A

Novel T Cell Bispecific For The

Treatment Of Solid Tumors

Adam Root, Senior Principal Scientist,

Pfizer






contact

[email protected]

10.00 – 11.00 Morning Coffee & Refreshments, One to One Meetings, Poster Presentation Sessions







& Generation






Multispecifics





contact

[email protected]



contact

[email protected]

11.30 – 12.00

Generating Antibodies Against GPCR And Ion

Channel Targets

Trevor Wilkinson, Associate Director,

AstraZeneca

Automation Of Laboratory Tasks And

Accelerating Learning Through Data And

Knowledge Management

Stephen Ashman, Director, Head of High-

Throughput Expression and

Characterization, GlaxoSmithKline

Developability Assessment Of Antibody

And Bispecifics Drugs At The Discovery

Stage

• Factors which may impact the developability

of monoclonal antibodies and various

formats of bispecific antibodies will be

reviewed

• The talk will outline a selection process

which enable the design, triage, and

optimization of antibody leads with

optimal physicochemical properties before

they reach the development phase, thereby

reducing the level of risk failure and

reducing development time to FIH

• The physico-chemical characterization,

candidate screening, and optimization and

early developability assessment of

candidate molecules will be discussed

Laurence Fayadat-Dilman, Senior Director,

Protein Sciences Head, Discovery Biologics,

MSD

Engineering Of A Bispecific Antibody

Tuned For Tissue Selective Binding Of

A Ubiquitously Expressed Antigen Therapeutic antigens of interest that are also

expressed on healthy tissues require a selective

targeting strategy to only target the antigen on

diseased tissue. This selectivity is necessary in order

to minimize toxicity and to ensure good

pharmacokinetic properties. We have developed a

detuning strategy to engineer bispecifics that

selectively bind to a ubiquitously expressed effector

antigen on target cells. We used a crystal structure of

the effector antigen bound to a high affinity Fab to

guide the construction of an in silico library of Fab

variants predicted to have a range of lower affinities,

good stability, and low immunogenicity. Variants from

this library were expressed as IgG bispecifics with an

antibody arm that provided target cell specificity, and

were screened for selectivity and potency. We

discovered a group of detuned bispecifics that

effectively bound to the effector antigen on target

cells co-expressing the selectivity antigen, but which

bound minimally to a non-target cell line that

expressed only the effector antigen. In vitro affinity

measurements with the extra-cellular domain of the

effector antigen revealed a 100 – 200-fold decrease in

affinity for these variants. In vivo and in vitro cell

based studies with the detuned bispecifics confirmed

effector-based cell killing and decreased binding to

non-target cell types relative to a monospecific

antibody. The detuned effector variant arms have

also been paired as bispecifics with other target

specific antibody arms and similar levels of target

cell-specific killing have been observed. Finally, we

have shown in that our strategy of avidity driven

specificity can be applied to other ubiquitously

expressed targets, demonstrating the robustness of

this approach.

Bellos Hadjivassiliou, Scientist II,

Celgene








& Generation






Multispecifics

12.00 – 12.30 mAb Generation Platform Updates

Francisca Wollerton, Director of Antibody

Engineering, F-star Biotechnology

The CAIMAN Project - Making Most Of Our

Data With D360

Digitalization is creating exciting new

opportunities. To be equally successful in this

new environment, Roche pRED depends on

making better use of our research data, which

continue to increase exponentially. The CAIMAN

project is part of the Lab of the future initiative

that addresses digitalization and supports the

overall pRED digitalization goals. Within the Lab

of the future we embrace digital and automated

solutions to aid discover and develop superior

biologics.

Marc Pompiati, Senior Scientist, Roche

Pharmaceuticals

High A flexible Automated mAb Production

Platform For Antibody Discovery And

Selection

Jacques Dumas, Head of Protein Sciences &

Technology, Sanofi

Model-Based Approaches To Guide

Design Of Multispecifics

Jennifer Fretland, Head of DMPK US,

Sanofi



contact

[email protected]



contact

[email protected]



contact

[email protected]



contact

[email protected]

13.00 – 14.00 Lunch, One to One Meetings x3, Poster Presentation Sessions









Part 2 - Biotherapeutics Discovery &

Development: Non-Oncology Indications






Multispecifics

14.00 – 14.30 Title To Be Confirmed

Chawaree Chaipan, Investigator II, Novartis

Recent Advances In Antibody

Manufacturing

Laura von Schantz, Director, Antibody

Engineering, Alligator Bioscience

Exploration Of Methods To Improve And

Streamline Expression Of Difficult

Membrane Proteins To Support Drug

Discovery

Integral membrane proteins represent more than

60% of current drug targets. Despite the clinical

significance, therapeutic agents that target

membrane proteins have been difficult to

develop. Poor expression in recombinant

systems is the most critical challenge to

producing functional integral membrane proteins

for antibody discovery, structural and functional

studies. The results from our on-going

exploration of different technologies for efficient

mammalian expression of several GPCRs and Ion

Channels through stable cell-line generation and

transient expression (DNA and BacMam) will be

presented.

Noel Byrne, Expression Group Lead and

Associate Principal Scientist, Merck

Research Laboratories

Discovery, Optimization, And

Developabilty Profiling Of Fragment-

Based And Common Light Chain CD3

Bispecifics

CD3 bispecifics represent a highly

promising therapeutic modality for cancer

treatment. CD3 antibodies displaying a

broad affinity range were produced as

bispecifics in either fragment-based (CD3

scFv) or common light chain (cLC) IgG-like

formats and their binding, biophysical, and

functional properties assessed. Adimab

engineering technology allows for CD3

affinity tuning in both formats. We are also

investigating pH-dependent CD3

antibodies with selective binding in the

acidic tumor microenvironment, a

potentially promising new angle for

reducing CD3 bispecific cytokine toxicity.

Robert Pejchal, Director, Antibody

Engineering, Adimab












Multispecifics

14.30 – 15.00 Pre-Clinical Characterization Of A Brain

Shuttle Anti-Amyloid Antibody

Brain uptake of therapeutic antibodies has been

reported using different experimental systems and

diverse methodologies, but the precise

measurement of drug levels in all relevant brain

compartments is often hampered by technical

difficulties. We present the comprehensive

characterization of a brain shuttle anti-amyloid

antibody in cynomolgus monkey, including

modeling-supported plasma and brain

pharmacokinetics.

Sabine Imhof-Jung, Principal Scientist, Roche

Pharma

Pharmacokinetic And Pharmacodynamic

Characterisation Of An Anti-Mouse TNF

Receptor 1 Domain Antibody Formatted

For In Vivo Half-Life Extension

Andrew Sanderson, Scientific Leader,

GlaxoSmithKline

Producing Recombinant Human Proteins

For Structure-Based Drug Design

Ciarán Cronin, Associate Research Fellow,

Head Parallel Protein Production Group, &

Group Leader Gene-to-Structure, Pfizer

Half-Life Extension Of Bispecific

Biologics – Pharmacokinetic And

Pharmacodynamic Consideration

Bispecific antibodies and peptides are

evolving in pipelines of pharma

companies. In oncology, bispecific T-cell

engagers showed great success with

Blinatumomab as a great example. Other

bispecific modalities in disease areas like

diabetes and immunology are promising.

The advantages of having a dual targeting

in one molecule include potential superior

efficacy versus monotherapy and easier

development and production compared to

fixed dose combination. Although some of

bispecific molecules are based on IgG

format which has intrinsically long half life,

many others are lacking Fc backbone and

can be cleared very quickly from

circulation. Many approaches are available

during discovery and preclinical

development to extend the half life and

duration of action of bispecific molecules

such as Fc fusion, pegylation and albumin

binding. These approaches will be

presented, their predictivity to clinical

pharmacokinetics and pharmacodynamics

will be discussed.

Youssef Hijazi, DMPK Expert, Sanofi




2nd Annual Bispecifics in Discovery &









Multispecifics

15.00 – 15.30 Efgartigimod, The FcRn Antagonist, i.e. The

Molecule, Phase 1 HV Study And The Phase 2

Studies In Myasthenia Gravis And Immune

Thrombocytopenia

Magdalena Sips, Senior Scientist, Argenx

Key Considerations For Biotherapeutic

Drug Disposition (PK, Bioanalysis And

Immunogenicity Evaluation)

Seema Kumar, Associate Director, MSD

The Discovery Of Novel Therapeutics

Against GPCRs, Ion Channels &

Transporters Using The Salipro®

Technology

The majority of small-molecule drugs target

multispanning membrane proteins. However, it's

been difficult to generate functional monoclonal

antibodies (mAbs) against this group of targets.

As a result, only a few therapeutic antibodies

have been approved when targeting this

important class of drug targets, including GPCRs,

Ion Channels and Transporters.

The key to make functional mAbs is to use pure,

native, homogeneous antigen for immunization,

mAb selection/sorting and for in vitro HTS

characterization. The Salipro® nano-membrane

technology enables all the above for fragile

membrane protein targets. In addition, Salipro®

represents a validated approach for membrane

protein epitope mapping by cryo-EM. Working

with Salipro® allows to unlock entirely novel

opportunities in drug discovery and antibody

development.

Robin Löving, Chief Scientific Officer,

Salipro Biotech

Bispecific Screening In Final Format

Guy Georges, Senior Principal

Scientist, Roche Pharmaceuticals

15.30 – 16.00 Afternoon Coffee & Refreshments, Poster Presentation Sessions

16.00 – 16.30 Discovery And Development Of Therapeutic

Antibodies For Cardiovascular Indications:

Challenges & Case Study

• Introduction to Cardiovascular Research at

Bayer

• General challenges when developing

antibodies for cardiovascular indications

• Lead discovery and optimization for Factor XIa

anti-thrombotic antibody

Fionnuala McAleese Eser, Antibody Lead

Discovery 1, Bayer AG

Design, Development And Applications Of

Bispecific Antibody Formats: A PKPD

Perspective

• Design Considerations for Bispecific and

Multivalent Antibody Therapeutics

• Development Considerations for Bispecific

and Multivalent Antibody Therapeutics

• PKPD consideration of Bispecifics and other

antibodies formats

• FIH dose selection of T cell Bispecifics

Rajbharan Yadav, Scientist, Development

Sciences, Genentech

Protein Expression Updates

Nicholas Brindle, Professor of Cell

Signalling, University of Leicester

Selective Targeting Of CD47 Mediated

By Bispecific Antibodies With

Unbalanced Affinities

• Engagement of a widely expressed

antigen on selected cell population is

feasible with bsAbs

• The relative affinities of the two arms

of the bsAb is of crucial importance

• Examples will be described

illustrating this mechanism of action

Nicolas Fischer, Chief Executive

Officer, Light Chain Bioscience – A

brand of Novimmune SA




2nd Annual Bispecifics in Discovery &









Multispecifics

16.30 – 17.00 Biotherapeutics Case Study

Colin Self, Emeritus Professor, Newcastle

University

Developability Screening For Lead

Selection- A More Balanced Approach

Assessing developability characteristics is now

the norm. However, there has to date been a

focus on manufacturing risks versus safety and

pharmacology (translational factors) early on in

the process. Our aim is to rebalance our

approach to developability screening to include

in vitro screens to address these areas. This talk

will give an update on our progress and discuss

the challenges and opportunities of this work.

Jennifer Drew, Investigator,

GlaxoSmithKline

The Development Of Small Protein

Domains For Biotechnological And Medical

Use Protein engineering and in vitro selection systems

are powerful methods for generating binding

proteins. By using combinatorial protein engineering

and protein library technologies, smaller antibody

fragments and alternative non-immunoglobulin

protein scaffolds can be engineered for various

functions based on molecular recognition. The focus

of our research is the development of protein-based

systems for purification and detection. The concept

to achieve binders for different purposes has been

developed by the design and selection of small

protein domains with bispecific properties. These

bispecific binding proteins have been selected and

designed for use both in protein purification

strategies as well as in diagnostic and therapeutic

applications. By radiolabeling one of our developed

HER2-binding domains, we have been able to very

selectively detect and image tumors in mice.

Furthermore, a first-in-human study shows that this

HER2-bining domain is safe, has favorable dosimetry

characteristics and can provide images of HER2-

expressing primary breast tumors and auxiliary

lymph node metastases and thus, is a promising tool

for evaluation of HER2 expression in breast cancer

using SPECT. Encourage by these results, we recently

started a therapeutic study where a bispecific

version of the HER2-binding domain is used. Here,

the development as well as the results from these

studies will be discussed.

Sophia Hober, Professor of Molecular

Biotechnology, KTH Royal Institute of

Technology

A Fully-Human Bispecific Antibody

For The Treatment Of Haemophilia A

• Loss of blood coagulation Factor VIII

(F.VIII) results in the bleeding

disorder, hemophilia A. Recently, a

novel treatment for hemophilia A

involving a humanized bispecific

antibody (BiAb), which mimics the

action of factor VIII, has been

developed, Hemlibra. Successful

approval of this BiAb provides new

therapeutic options for patients.

• Kymab’s IntelliSelect Transgenic®

antibody discovery platform

generates fully-human antibodies,

(removing the need for humanization

of isolated antibodies) so isolated

antibodies do not require a

humanization step. Integrating

Kymab’s IntelliSelect® Transgenic and

IntelliSelect® Bispecific platforms, we

sought to develop a fully human F.VIII

common light chain (CLC) bispecific

antibody that can mimic the action of

F.VIII in vivo. We characterized

isolated and optimized BiAbs using

clinically relevant haemostatic assays.

• KY1049, developed using Kymab’s

IntelliSelect® Bispecific platform, is a

potent F.VIII mimetic bispecific

antibody with comparable activities

to a sequence-identical analogue of

Hemlibra. KY1049 represents, to date,

the first fully-human F.VIII mimetic

CLC BiAb with both heavy chains

naturally binding a cognate CLC.

Expression and purification of KY1049

meets current manufacturing

standards.

John Blackwood, Senior Research

Scientist, Kymab












Multispecifics

17.00 – 17.30 Presentation To Be Confirmed

A Fully Automated Analytical Platform

Enabling High-Throughput Bispecific

Mispairing Assessment

• For bispecific mAb development, Mass

spectrometry becomes important to provide

analytical readout on mispairing assessment

• At Novartis Biologics Center, a fully

automated workflow was established to

enable automated data analysis and

reporting

• The platform facilitates a large scale analysis

in a high-throughput fashion

Yang Yang, Scientific Technical Leader,

Novartis

Production Of Therapeutic Proteins

Alexander Frey, Associate Professor,

Molecular Biotechnology, Aalto University

FAP-4-1BBL: A Tumor-Stroma

Targeted Costimulatory Agonist For

Cancer Immunotherapy

4-1BB agonism is successfully used in CAR

T cell therapy. However antibody-mediated

4-1BB agonism has shown several

drawbacks in clinical research due to

toxicity or limited efficacy. April 2018 FAP-

4-1BBL, developed at the Roche Innovation

Center Zurich, entered the clinic (Phase I).

In this presentation the focus will be on

the pre-clinical development of a novel

tumor-stroma targeted 4-1BB agonist as a

promising combo-partner for anti-cancer

immunotherapy. Shown data will be based

on two recent publications (C. Claus et al.

Sci Transl Med. 2019 Jun 12;11(496) and F.

Uhlenbrock 2020 (under review)).

Christina Claus, Senior Scientist,

Roche Pharmaceutical Research and

Early Development (pRED)

17.30 End of Congress

I cannot attend but would like to purchase access to the following:

Access to the online conference presentations £499 plus VAT VAT is charged at 20% on the attendance fees for all delegates. VAT is also charged on online and paper copy documentation and promotional literature distribution for all UK customers and for those EU customers not supplying a registration number for their own country here.

Biologics Series

13th Annual Proteins & Antibodies Congress | 7th Annual Peptides & Oligonucleotides Congress 2nd Annual Bispecifics in Discovery & Development Congress

27 - 29 April 2020, Novotel London West, London, UK www.oxfordglobal.co.uk/biologics-series/

HOW TO REGISTER: FAX your booking form to +44(0)1865 689120 | PHONE on +44(0)1865 248455 | EMAIL: [email protected]

Agreed Terms between the Organiser (Oxford Global Marketing Ltd) and the Delegate:

Delegate Booking Fee The Delegate Booking Fee includes: lunches and refreshments throughout the Series, presentations and panel sessions, scheduled one-to-one meetings and networking/social events, Series and speaker notes. Delegates may attend, free of charge, all sessions arranged by the Organiser.

An admin surcharge of £50 plus VAT will be applied to payments settled following the receipt of an invoice. This charge will not be applied to payments settled online. Vendor Delegates will not be eligible for one to one meetings unless they purchase a sponsorship meetings package. These can only be purchased directly from Oxford Global Marketing Ltd and not via the online booking facility.

Acceptance of a Complimentary Pass If you are offered a free delegate pass and you are unable to attend the Series, you may nominate a substitute of equal standing (in terms of business and financial responsibility). A substitute delegate must be nominated within a week of cancellation and must be approved by the Organiser in ad-vance in order to avoid a non-attendance charge of £200 plus VAT being applied. Your complimentary delegate place is not officially confirmed until we have had chance to check that you qualify for the complimentary pass. Please do not make any travel arrangements before we have confirmed acceptance of your application. We will not be liable for any expenses incurred.

Delegate Registration Form Each Delegate must complete the online delegate registration form issued by the Organiser on receipt of the Delegate Booking Form. This information will only be used for the organisation of the Series, for material produced for Delegates and Sponsors and to facilitate the networking sessions.

Cancellation and Curtailment If a Registered Delegate is unable to attend the Series, he/she may nominate a substitute of equal standing within their Company. A substitute delegate must be nominated within a week of cancellation and must be approved by the Organiser in advance in order to avoid cancellation charges being applied. Delegates and vendor delegates are subject to the following charges and refunds upon withdrawal or cancellation.

More than 6 months prior 35% cancellation fee / 65% refund Between 6 and 3 months prior 75% cancellation fee / 25% refund Less than 3 months prior to the event Full cancellation fee / No refund

Data Protection The data controller is the organiser (Oxford Global Marketing Ltd). Registration details will be retained and used in accordance with our privacy policy. Your information may be shared with selected partners and contractors, solely for the for the purposes of the event. Please note: If you attend an event then a sponsor or exhibitor may scan your badge. This is the equivalent to handing over your business card. Should you allow your badge to be scanned then Oxford Global will share your Personal Information with the relevant sponsor or exhibitor. If you register for a sponsor-led workshop or session (by actively selecting this option at the point of registration or allowing your badge to be scanned on entry to the session), you are agreeing to share your personal information with the named sponsor

Miscellaneous The Organiser will determine the scope and content of Series events, seminars, workshops and activities throughout the Series. The Organiser reserves the right to cancel the Series without liability to Delegate’s Company or individual Delegate. If for any reason the Organiser has to cancel or postpone this Series, the Organiser reserves the right to transfer this Booking to another Series within the same sector to be held within twelve months. Should another Series in the same sector not be available within this period, the Booking Fee will be refunded. For promotional purposes, there may be professional photography and video production taking place during the Series. Delegates who do not wish to be filmed or recorded should advise the organisers by email to [email protected] prior to the event. These terms and conditions are binding upon the delegate submitting a registration form.

If you have any further queries please call the marketing team on +44(0)1865 248455 or email [email protected]

Delegate Details

Terms & Conditions of Booking

I agree to the above Terms and Conditions

Registration Fees

Documentation

How to Pay (choose one of the following payment options)

I would like to attend: (Please tick as appropriate) Industry Delegates (Biopharma, Pharma or Biotech Companies) 2-day pass £899 plus VAT 1-day pass £599 plus VAT Day 1 (with complimentary access to the pre-event workshop) Day 2 Day 3 Academic Delegates 2-day pass £520 plus VAT 1-day pass £320 plus VAT Day 1 (with complimentary access to the pre-event workshop) Day 2 Day 3 Vendor Delegates (CROs, Consultants, Technology and Service Providers) Series Only £1750 plus VAT Poster Presentation £250 plus VAT PROMOTIONAL LITERATURE DISTRIBUTION Distribution of your company’s promotional literature to all Series attendees £999 plus VAT

Number of delegates:

Industry del(s) Academic dels(s) Vendor dels(s)

Special Offer: 3 for 2 Offer is only valid on the Series and for those registering at Industry or Academic rates

Please choose one of the following payment options:

CREDIT CARD:

An Oxford Global representative will contact you directly following return of contract / booking form to process card payment. If payment will be made by a colleague within your company, please complete the following;

Card Payment Contact Name: ___________________________________

Phone Number: _________________________________________________ INVOICE:

Invoice Address (if different from above) ________________________

__________________________________________________________________

__________________________________________________________________

*Please note there is a £50 plus VAT handling charge for payment via invoice

Please complete fully and clearly. Please photocopy for additional delegates. Please tick which event(s) in the Series you are interested in: Proteins & Antibodies Congress Bispecifics Congress Peptides & Oligonucleotides Congress Title:_____ Forename:__________________ Surname:__________________ Job Title:___________________________________________________________ Company/Organisation:___________________________________________ Email:_____________________________________________________________ Address:___________________________________________________________ Postcode: ________________________ Country: _________________________ Direct Telephone _______________ Direct Fax: ________________ Mobile: ________________________ Switchboard: _____________ Signature: ______________________ Date: ___________________________

https://www.oxfordglobal.co.uk/biologics-series/




2020 speakers include - oxford global · including fusion proteins, antibody-drug conjugates,...

Documents